Biohaven spends $105M for faster review of oral CGRP inhibitor

Biohaven bought a $105 million Priority Review voucher from GW Pharmaceuticals to expedite the entry of its oral migraine therapy into the CGRP inhibitor market. It plans to use the voucher on an NDA for Zydis rimegepant, which it plans to submit to FDA next quarter.

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) paid a premium for the voucher compared with recent voucher sales, which have gone for about $80 million. Since the first voucher was issued in 2009, prices have ranged from $67.5 million to $350 million (see "Lilly Buys Siga's Priority Review Voucher Gained via Smallpox Approval")...